Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2003 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.
Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T, Miller DH; European Study Group on Interferon Beta-1b in Secondary Progressive MS. Molyneux PD, et al. Neurology. 2001 Dec 26;57(12):2191-7. doi: 10.1212/wnl.57.12.2191. Neurology. 2001. PMID: 11756596 Clinical Trial.
The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS.
Brex PA, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry TA, Hahn D, Rolland Y, Salonen O, Pozzilli C, Polman CH, Thompson AJ, Kappos L, Miller DH; European Study Group on Interferon beta-1b in Secondary Progressive MS. Brex PA, et al. Neurology. 2001 Dec 26;57(12):2185-90. doi: 10.1212/wnl.57.12.2185. Neurology. 2001. PMID: 11756595 Clinical Trial.
METHODS: One hundred twenty-five patients with secondary progressive MS from seven European sites were randomized to receive either IFNbeta-1b or placebo. Monthly, contrast-enhanced T1-weighted MR images were acquired at baseline, at months 1 to 6, and at months 19 to 24. …
METHODS: One hundred twenty-five patients with secondary progressive MS from seven European sites were randomized to receive either I …
MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b.
Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH, Kappos L, Filippi M; European Study Group on Interferon Beta-1b in Secondary Progressive MS. Sormani MP, et al. Neurology. 2003 May 13;60(9):1462-6. doi: 10.1212/01.wnl.0000063312.15758.b3. Neurology. 2003. PMID: 12743232 Clinical Trial.
METHODS: A validation procedure was applied to the clinical and MRI data collected in the context of the European randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNbeta-1b) in patients with secondary progressive MS. ...
METHODS: A validation procedure was applied to the clinical and MRI data collected in the context of the European randomized, double- …